Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling ...

Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...

Base editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets ...

Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce ...

Highlight Therapeutics touted positive topline results in patients with localized high-risk head and neck basal cell ...

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...

Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose. | Amgen has shed light on its ...

The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...

UniQure filed for accelerated FDA approval early this month. (uniQure) uniQure’s Huntington’s disease gene therapy has failed ...

A newly launched $5 million clinical trial program allows clinical trial sponsors to start trials in as little as 45 days in the Canadian province Ontario. | A newly launched $5 million clinical trial ...

Merck paid Daiichi $4 billion upfront in 2023 to partner on three ADCs. The FDA rejected a request for approval of one of the ...

AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab ...